Senior/Executive Director, Regulatory Affairs

Bachelor's degree and a minimum of 12 years of direct experience in Regulatory Affairs; rare disease, neurology, CMC, advanced degree (MS, PharmD, PhD), and/or combination product experience a plus.

Demonstrated track record of successful interactions with FDA and other Health Authorities.

Expert understanding of scientific principles and regulatory requirements relevant to global drug development.

Preparation of nonclinical and clinical sections of regulatory filings, including IND/CTAs, PIPs, briefing documents, and BLA/MAAs.

Preparation for and conduct of Regulatory meetings with global Health Authorities for complex issues.

Strong interpersonal skills and the ability to collaborate effectively with subject matter experts.

The Senior Director/Executive Director of Regulatory Affairs will develop and execute global regulatory strategies in collaboration with key stakeholders.

You will serve as the global regulatory lead for our new asset (DNTH212) in multiple programs, providing expert guidance to cross-functional teams, driving global regulatory submissions, acting as primary liaison with Health Authorities, and interpreting applicable Health Authority regulations and guidance documents to ensure compliance.

This is a unique opportunity to join a growing organization with an expanding pipeline, and to play an integral role in the in the global development of assigned programs from early phase through marketing approval. We are building a culture of individuals who hold our core principles at the center of our operations, with the goal to elevate the care of our patients’ lives. We are open to you working remotely within the contiguous United States or Canada.

Represent regulatory on cross-functional teams; provide leadership and strategic direction for regulatory deliverables.

Lead planning and provide hands-on support for development and on-time delivery of clear and persuasive global regulatory submission documents, including INDs/CTAs, DSURs, pediatric investigation plans (PIPs), responses to Health Authority (HA) queries, and briefing documents.

We are developing potentially best in class therapies for patients living with severe autoimmune diseases. Our lead antibody, claseprubart (DNTH103), is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology – enabling less frequent and more convenient self-administered subcutaneous injections. Our second clinical candidate, DNTH212 is a first and potentially best in class, bifunctional inhibitor that targets clinically validated and complementary disease modifying mechanisms, Type 1 IFN suppression and B cell modulation – enabling potential for improved clinical outcomes and patient friendly convenient, self-administered subcutaneous injections. To learn more, please visit

www.dianthustx.com

and follow us on

LinkedIn

.